Beyond Obesity: Eli Lilly's Genetic Medicine Bet On Verve Therapeutics

1. Eli Lilly acquires Verve Therapeutics for $1.3 billion, a 113% premium. 2. The acquisition enhances Lilly’s portfolio in cardiovascular genetic medicine. 3. Lilly's P/E remains below its three-year average despite premium paid. 4. Key risks include market volatility and portfolio concentration on obesity drugs. 5. Strong performance in obesity treatments supports acquisition strategy.